Author: Italfarmaco

Italfarmaco Announces Managed Entry Agreement in Georgia for Givinostat as Treatment for Patients with Duchenne Muscular Dystrophy

July 31, 2026
Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment

June 10, 2026

Italfarmaco Announces Managed Entry Agreement in Georgia for Givinostat as Treatment for Patients with Duchenne Muscular Dystrophy